| [1] |
Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)[J]. J Clin Endocrinol Metab, 2012, 97(9): 2990-3011.
|
| [2] |
Lodewijk L, Bongers PJ, Kist JW, et al. Thyroid incidentalomas in patients with multiple endocrine neoplasia type 1[J]. Eur J Endocrinol, 2015, 172(4): 337-342.
|
| [3] |
Niederle B, Selberherr A, Bartsch DK, et al. Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome - An international consensus statement[J]. Neuroendocrinology, 2021, 111(7): 609-630.
|
| [4] |
Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)[J]. Mol Cell Endocrinol, 2014, 386(1-2): 2-15.
|
| [5] |
Frederiksen A, Rossing M, Hermann P, et al. Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases[J]. J Clin Endocrinol Metab, 2019, 104(9): 3637-3646.
|
| [6] |
Marini F, Giusti F, Iantomasi T, et al. Parathyroid tumors: molecular signatures[J]. Int J Mol Sci, 2021, 22(20): 11206.
|
| [7] |
Kong J, Wang O, Nie M, et al. The expression of p27Kip1 and β-catenin in multiple endocrine neoplasia type 1-related parathyroid tumors[J]. Zhonghua Nei Ke Za Zhi, 2016, 55(11): 859-862.
|
| [8] |
Marx SJ, Goltzman D. Evolution of our understanding of the hyperparathyroid syndromes: A historical perspective[J]. J Bone Miner Res, 2019, 34(1): 22-37.
|
| [9] |
Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy[J]. Cell, 2012, 150(1): 12-27.
|
| [10] |
Donati S, Ciuffi S, Marini F, et al. Multiple endocrine neoplasia type 1: the potential role of microRNAs in the management of the syndrome[J]. Int J Mol Sci, 2020, 21(20): 7592.
|
| [11] |
Marx SJ. New concepts about familial isolated hyperparathy-roidism[J]. J Clin Endocrinol Metab, 2019, 104(9): 4058-4066.
|
| [12] |
Hackeng WM, Dreijerink KMA, Offerhaus GJA, et al. A parathyroid-gut axis: hypercalcemia and the pathogenesis of gastrinoma in multiple endocrine neoplasia 1[J]. Mol Cancer Res, 2021, 19(6): 946-949.
|
| [13] |
Liu P, Vakharia N, Zacharia A, et al. Bilateral giant parathyroid adenoma in the absence of multiple endocrine neoplasia type 1[J]. Ann R Coll Surg Engl, 2020, 102(6): e111-e114.
|
| [14] |
Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 21 years old: A 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines[J]. J Clin Endocrinol Metab, 2015, 100(4): 1568-1577.
|
| [15] |
Herath M, Parameswaran V, Thompson M, et al. Paediatric and young adult manifestations and outcomes of multiple endocrine neoplasia type 1[J]. Clin Endocrinol (Oxf), 2019, 91(5): 633-638.
|
| [16] |
Giusti F, Cianferotti L, Boaretto F, et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database[J]. Endocrine, 2017, 58(2): 349-359.
|
| [17] |
Di Meo G, Sgaramella LI, Ferraro V, et al. Parathyroid carcinoma in multiple endocrine neoplasm type 1 syndrome: case report and systematic literature review[J]. Clin Exp Med, 2018, 18(4): 585-593.
|
| [18] |
Versnick M, Popadich A, Sidhu S, et al. Minimally invasive parathyroidectomy provides a conservative surgical option for multiple endocrine neoplasia type 1-primary hyperparathyroidism[J]. Surgery, 2013, 154(1): 101-105.
|
| [19] |
Lairmore TC, Govednik CM, Quinn CE, et al. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1[J]. Surgery, 2014, 156(6): 1326-1335.
|
| [20] |
Tonelli F, Marcucci T, Fratini G, et al. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1?[J]. Ann Surg, 2007, 246(6): 1075-1082.
|
| [21] |
Moyes VJ, Monson JP, Chew SL, et al. Clinical use of cinacalcet in MEN1 hyperparathyroidism[J]. Int J Endocrinol, 2010, 2010: 906163.
|
| [22] |
Filopanti M, Verga U, Ermetici F, et al. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly[J]. Eur J Endocrinol, 2012, 167(2): 157-164.
|
| [23] |
Del Prete M, Marotta V, Ramundo V, et al. Impact of cinacalcet hydrochloride in clinical management of primary hyperparath-yroidism in multiple endocrine neoplasia type 1[J]. Minerva Endocrinol, 2013, 38(4): 389-394.
|
| [24] |
Giusti F, Tonelli F, Brandi ML. Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery?[J]. Clinics (Sao Paulo), 2012, 67 Suppl 1: 141-144.
|
| [25] |
Singh Ospina N, Thompson GB, Lee RA, et al. Safety and efficacy of percutaneous parathyroid ethanol ablation in patients with recurrent primary hyperparathyroidism and multiple endocrine neoplasia type 1[J]. J Clin Endocrinol Metab, 2015, 100(1): E87-E90.
|
| [26] |
Schreinemakers JM, Pieterman CR, Scholten A, et al. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: A systematic review[J]. World J Surg, 2011, 35(9): 1993-2005.
|
| [27] |
Waldmann J, López CL, Langer P, et al. Surgery for multiple endocrine neoplasia type 1-associated primary hyperparath-yroidism[J]. Br J Surg, 2010, 97(10): 1528-1534.
|
| [28] |
Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients[J]. World J Surg, 2010, 34(2): 249-255.
|
| [29] |
de Laat JM, van der Luijt RB, Pieterman CR, et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients[J]. BMC Med, 2016, 14(1): 182.
|